It is particularly important to fill these knowledge gaps, as LOX has been shown to be a promising target for therapeutic intervention in cancer [3,78,79] and in vascular [80], myocardial [81,82], peritoneal [83] liver [84] and urological disorders [85], in adipose tissue dysfunction with an inflammatory component [86] and in inflammation in Crohns’ disease [87]. This evidence concerns the gene LOX and urinary system disorder.